Global Women’s Healthcare
Market – Market Outlook & Trends
Global Women’s Healthcare Market appraised at USD 9.6 billion in 2019 is
expected to reach USD 23.81 billion by 2026, at a CAGR of 13.2 % during the
projection period. The market's growth is mainly driven by factors such as the
rising incidence of chronic illnesses among women, government initiatives to
curb population, and growing requests for contraceptives to avoid unintentional
pregnancies. Moreover, the growing focus on R&D by key players for the
development of advanced products is also another major factor contributing to
The increasing female
population aged over 60, adoption of unhealthy routine, and innovative
medicines induce market growth. Furthermore, promising policies implemented by
the government to improve women's health and raise awareness are likely to
drive market development during the projection period. Women are at advanced
risk of illnesses such as menstrual health-related disorders, osteoporosis,
osteoarthritis, anemia, depression, and obesity. Hence, growing occurrences of
these conditions are likely to increase the market development in the coming
Global Women’s Healthcare
Market – Overview
Women's health is
concerned with the ailments and treatment related to her anatomy and
reproductive organs. A woman encounters several issues related to menstruation,
pregnancy, menopause, and others during her life. Women's health also includes
medical situations in which women face problems not directly linked to their
biology but due to gender-differentiated admittance to medical cure. Women's
health issues have gained increasing recognition in recent decades worldwide.
Effective policies and government initiatives have led to a reduction in
women's ailments and have allowed them to live healthier lives. However, some
significant gender-based health disparities prevail in many countries. Lack of
awareness and lower-income levels in many developing countries remain obstacles
making health progress for women very difficult.
Increasing prevalence of
age-related health disorders in women
Chronic ailments and
reproductive issues affect women's health mostly. The factors such as physical
inactivity, smoking, alcohol use, depression, and no availability of health
services adversely affect women's health. Most women aged 15 to 44 suffer from
one of the other sexual and reproductive health problems. Hormonal imbalance
concerning prolactin, estrogen, and thyroid is growing in women due to stress
and other deficiencies, further triggering demand for the medicine to improve
health. The hormonal infertility is anticipated to rise rapidly due to
unfavorable conditions in advanced countries and will lead to market growth
over the projection period.
Rising Focus on Women's
Health by Government and Private Organizations
Governments and various
private organizations worldwide emphasize women's health and wish to deliver
maximum healthcare benefits while designing and implementing health policies
and plans. Progressive coverage plans for women are likely to induce the market
in advanced countries. For instance, numerous coverage plans in the US provide
preventive services for women without any corresponding charges. The preventive
services comprise regular anemia screening, folic acid supplements for pregnant
women, hepatitis B tests, breast cancer screening, and contraception.
Department of Health and Human Services has recognized the Healthy People 2020
program spanning over ten years to improve the fitness of all Americans.
Global Women’s Healthcare
Market – Segmentation
Based on the drug, the
market is divided into Mirena, Zometa, Reclast, Prolia, Xgeva, Evista,
Nuvaring, Primarin, and Actonel. Prolia is the fastest-growing section of the
market. It also registered the highest market share in 2018. The high
prevalence of postmenopausal osteoporosis among women is the main factor
responsible for this market segment's growth.
The market is divided
into contraceptives, menopause, PCOS, hormonal infertility, postmenopausal
osteoporosis, endometriosis, and other applications, based on application. In
2018, the postmenopausal osteoporosis section remained the leading market
division during the prediction period. Rising occurrence of postmenopausal
osteoporosis, more emphasis on providing a real cure for postmenopausal issues,
and high risk of osteoporosis fractures maintained this segment's development.
Moreover, factors such as old age and obesity further add to the risk of
osteoporosis in women. Therefore, his section is also expected to register the
maximum CAGR during the prediction period.
Based on the region,
Global Women’s Healthcare Market is segmented by key regions— North America,
Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Global Women’s Healthcare
Market - Regional Insights
The global women’s
healthcare market is divided into five major areas: North America, Europe,
APAC, Latin America, and the Middle East & Africa. In 2018, North America
was the main and the fastest-growing area market for women’s healthcare. The
significant factors driving market development include the rising incidence of
PCOS and postmenopausal osteoporosis, the growing median age of first-time
pregnancies, and increased healthcare expenditure in the US and Canada. Also,
the high awareness regarding contraceptives among American women and the easy
access to modern contraception compared to emerging countries propel the market
development in this region.
The prominent in women's
healthcare are Eli Lilly and Company, Novartis AG; Pfizer Inc., Merck &
Co., Inc.; Novo Nordisk A/S; Amgen Inc., Lupin Pharmaceuticals, Inc.,
AstraZeneca, F. Hoffmann-La Roche Ltd, Sanofi, Johnson & Johnson Services
Inc., GlaxoSmithKline plc, Bayer AG, Theramex, Agile Therapeutics, Blairex
Laboratories Inc., Bristol-Myers Squibb Company, Ferring B.V., Abbott, Enteris
BioPharma, Evestra, Inc, Gedeon Richter, HRA Pharma, JDS Therapeutics, LLC,
Neurocrine Biosciences Inc., Noven Pharmaceuticals, Inc., Radius Health, Inc.,
TherapeuticsMD Inc., Bausch Health, Vertical Pharmaceuticals LLC, Veru Inc., BD
and AbbVie Inc. and others.
In February 2018, CVC VI
announced that it had formed a new company known as Theramex that will provide
products and therapeutics to women for contraception, fertility, menopause, and
osteoporosis. The company will be located in London, England. Its products will
be available at the company’s disposal after the acquisition of Teva
Pharmaceutical Industries Ltd.’s women's health offerings.
Scope of the Report
Historical data – 2016-2019
Base Year – 2019
Forecast – 2020 – 2026
Revenue in USD Billion
U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Japan, South Korea, China, India, South Korea UAE, South Africa, Saudi Arabia.
By Drug, By Application and By Region
Eli Lilly and Company, Novartis AG; Pfizer Inc., Merck & Co., Inc.; Novo Nordisk A/S; Amgen Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Sanofi, Johnson & Johnson Services Inc., GlaxoSmithKline plc, Bayer AG, Theramex, Agile Therapeutics, Blairex Laboratories Inc., Bristol-Myers Squibb Company, Ferring B.V., Abbott, Enteris BioPharma, Evestra, Inc, Gedeon Richter, HRA Pharma, JDS Therapeutics, LLC, Neurocrine Biosciences Inc., Noven Pharmaceuticals, Inc., Radius Health, Inc., TherapeuticsMD Inc., Bausch Health, Vertical Pharmaceuticals LLC, Veru Inc., BD and AbbVie Inc.
Ø Minastrin 24 Fe
Ø ORTHO TRI-CY LO (28)
Ø Hormonal Infertility
Ø Postmenopausal Osteoporosis
Ø Polycystic Ovary Syndrome
Ø Other Applications
Ø North America
Ø Asia Pacific
Ø Latin America
Ø Middle East & Africa
The objective of the Study:
Ø To analyze and project the Global Women’s Healthcare Market
size in terms of value.
Ø To examine the region-wise segmentation of the Global Women’s Healthcare Market and assess the market size in
terms of value for each region viz., North America, Europe, Asia Pacific,
Middle East & Africa, Latin America, and their leading countries.
Ø To outline, segregate, and estimate the Global Women’s Healthcare
Market based on different classifications, i.e., By Drug, By Application
and By Region.
Ø To scrutinize category-wise competitive developments in the Global Women’s Healthcare Market By Drug, By Application and By
Ø To interpret the current market dynamics by analyzing growth
drivers, restraints, opportunities, and challenges and their impact.
Ø To provide a detailed competitive landscape, including major
players, strategic profiles, and market shares.
Business Questions Answered by the Report
Ø How will the market drivers, restraints, and opportunities
affect the market dynamics?
Ø What will be the market size in terms of value and volume and
market statistics with a detailed classification?
Ø Which segment dominates the market or region, and which one will
be the fastest-growing, and why?
Ø Who are the key players in the market, and what is their share?
Ø What is the strategy adopted by key players, and how does it
affect the existing and new players?
Customization Scope for the Client
Client satisfaction is our first and last priority, and that is
why BlueWeave Consulting offers customization as per client’s specific needs.
The following customization options are available for the report:
Ø Additional Company Information
Ø Detail Analysis of five additional companies
Ø Additional country analysis
Ø Detailed segment analysis